No Data
No Data
Nanjing Hicin Pharmaceutical Co., Ltd.'s (SZSE:300584) Stock Is Rallying But Financials Look Ambiguous: Will The Momentum Continue?
As of July 19th, Nanjing Hicin Pharmaceutical (300584.SZ) had a total of 14,162 shareholders.
Nanjing Hicin Pharmaceutical (300584.SZ) stated on the investor interaction platform that as of the close of July 10, the number of shareholders in the company was 13,705, and as of the close of July 19, the number of shareholders in the company was 14,162.
Shareholder Li Xiaquan reduced holdings of 782,700 shares of Nanjing Hicin Pharmaceutical (300584.SZ), reducing their holdings to less than 5%.
Nanjing Hicin Pharmaceutical (300584.SZ) issued an announcement that the company recently received a "Summary Equities Change Report" from shareholder Xiaquan Liu. As of the date of this announcement, Xiaquan Liu reduced the company's shares by 782,700 shares through centralized bidding, accounting for 0.65225% of the company's current total share capital. After this equity change, Xiaquan Liu's total shareholding in the company accounts for 4.99992% of the company's total share capital, and is no longer a shareholder holding more than 5% of the company.
Nanjing Hicin Pharmaceutical (300584.SZ): Received notification of approval for listing of chemical raw materials for propofol propofol Trovafloxacin.
On June 17th, Gelonhui reported that Nanjing Hicin Pharmaceutical (300584.SZ) received a notification of approval for the application to market chemical raw materials from the National Medical Products Administration. The chemical raw material name is Propofol fumarate Tenofovir alafenamide. Propofol fumarate Tenofovir alafenamide (TAF) is a prodrug of Tenofovir disoproxil fumarate (TDF), which is a potent antiviral drug. It has higher stability in plasma and can be more effectively delivered to liver cells, thus significantly reducing the risk of side effects by requiring much lower doses of TDF to achieve similar antiviral effects, with better bone and kidney safety.
Hicin Pharmaceutical Gets Registration Certificate for Tenofovir Alafenamide Fumarate Tablet
Nanjing Hicin Pharmaceutical (300584.SZ): Propofol substitute nucleoside antiviral tablets obtained drug registration approval.
On June 12th, Gelonhui reported that Nanjing Hicin Pharmaceutical (300584.SZ) recently received the "Drug Registration Certificate" issued by the State Drug Administration, with the drug name being propofol tenofovir tablets. The main ingredient of propofol tenofovir tablets is tenofovir alafenamide fumarate (TAF), which is a prodrug of tenofovir disoproxil fumarate (TDF), a potent antiviral drug. TAF has higher stability in plasma and can be more effectively delivered to liver cells, so the required dose for similar antiviral effect is far lower than TDF, significantly reducing the risk of side effects and having better bone safety.
No Data